Skip to content

A randomised controlled trial of combination versus single antipyretic treatment in febrile children

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN30487061
Enrollment
160
Registered
2005-02-23
Start date
2002-11-26
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fever Signs and Symptoms Fever

Interventions

1. Experimental group: A single dose (10 mg/kg) of Ibuprofen at zero time, followed by a single dose (15 mg/kg) of Acetaminophen at time = 4 hours 2. Control group: A single dose (10 mg/kg) of Ibuprof

Sponsors

American University of Beirut (Lebanon)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age between 6 months and 14 years 2. Rectal temperature greater than or equal to 38.8°C 3. Consent of treating physician 4. Consent of parent(s) and child if old enough to give consent (greater than 7 years) 5. No antipyretic intake for 8 hours prior to enrolment

Exclusion criteria

Exclusion criteria: 1. Presence of concurrent hepatic or renal disease 2. Chronic and/or serious disease such as malignancy, septic shock, malabsorption syndromes etc. 3. Any condition that may interfere with the absorption of the investigational drugs such as gastritis, diarrhoea, ileus etc. 4. Hypersensitivity to acetaminophen or ibuprofen 5. Bleeding disorder or tendency 6. Asthma

Design outcomes

Primary

MeasureTime frame
The primary endpoint of this study is the proportion of children in each group, with body temperature of 37.8°C or less at time 6 hours.

Secondary

MeasureTime frame
Secondary endpoints include the proportion of children in each group, with body temperarures of 37.8°C and below, at times 7 and 8 hours, and the change in hourly temperature from baseline, at times 4, 5, 6, 7, 8 hours. The proportion of patients in each group with any immediate adverse effect (within 24 hours from administration) that may be related to either drug, such as gastrointestinal bleed, hypothermia or others.

Countries

Lebanon

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026